JHVEPhoto/iStock Editorial via Getty Images
Shares of Teva Pharmaceutical (NYSE:TEVA) traded higher in the premarket on Wednesday after the generic drugmaker cited unfavorable forex movements as its revenue for the first quarter of 2025 fell short of Street forecasts.
The Israeli company posted $3.9B in revenue